Saudi Arabia Plasma Fractionation Market: Rising Immunoglobulin Demand, Biologics Expansion & Growth Outlook

The healthcare sector in Saudi Arabia is seeing significant momentum in specialized medical treatments, with rising demand for advanced therapeutic solutions across multiple patient segments. Better access to diagnostic services, increasing healthcare spending, and stronger government support are all driving this forward. According to IMARC Group's latest data, The Saudi Arabia plasma fractionation market size reached USD 349.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 733.6 Million by 2034, exhibiting a growth rate (CAGR) of 8.59% during 2026-2034.

Saudi Arabia is witnessing a notable transformation in its approach to plasma-derived therapies. These treatments, which include immunoglobulins, albumin, and coagulation factors, play a critical role in managing a range of serious medical conditions from blood disorders to immune deficiencies. The country's healthcare infrastructure is becoming more sophisticated, and patients now have better access to specialized care that was previously limited. Hospitals and clinics across the Kingdom are expanding their capabilities to handle complex treatment protocols, which is pushing demand for high-quality plasma products upward. The market is also benefiting from partnerships between local healthcare authorities and international pharmaceutical companies that bring expertise in plasma fractionation technologies.

Get a Sample Report for Actionable Market Insights

Saudi Arabia Plasma Fractionation Market Growth Drivers:

● Rising Aging Population

The expanding elderly demographic in Saudi Arabia is creating substantial new demand for plasma-based treatments. Older adults typically face weakened immune systems, making them more vulnerable to infections and chronic conditions that require immunoglobulin therapies derived through plasma fractionation. This age group also experiences higher rates of surgical procedures and hospitalizations, which further drives the need for albumin and clotting factors. The Saudi healthcare system is actively working to meet the specific medical requirements of seniors, leading to improved treatment access and greater utilization of specialized plasma products. By 2030, projections indicate that over 11% of Saudi Arabia's population will be aged 60 and above, representing a significant patient base requiring consistent medical interventions involving plasma-derived therapies.

● Increasing Prevalence of Chronic Diseases

The rising burden of chronic conditions across Saudi Arabia is fueling market expansion. Diseases such as hemophilia, primary immunodeficiency disorders, liver cirrhosis, and various autoimmune conditions require ongoing plasma-derived therapy for effective patient management. A research study conducted at King Abdulaziz Medical City in Riyadh analyzed 839 autoimmune disease cases as of May 2024, with women comprising 56.4% of participants. The findings revealed hypothyroidism as the most common condition at 6.8%, followed by alopecia areata at 3.6% and atopic dermatitis at 2.9%. These numbers reflect the growing patient pool requiring immunoglobulins, clotting factors, and albumin. Healthcare providers across the Kingdom are increasingly relying on plasma-based products to deliver better therapeutic outcomes, particularly as diagnostic capabilities improve and awareness grows among both medical professionals and patients.

● Growing Research and Development Activities

Intensifying research efforts and development initiatives are playing a major role in market advancement. Researchers and pharmaceutical companies are investing heavily in developing more advanced fractionation methods to enhance both the efficiency and safety of plasma-derived products. Saudi Arabia has set ambitious targets for research spending, aiming to reach 2.5% of GDP by 2040. These efforts are yielding new therapies for immune deficiencies, hemophilia, and various blood-related disorders. Continuous innovation is improving purification processes, increasing product yield, and reducing contamination risks. The Kingdom's growing emphasis on biotechnology and healthcare modernization is supporting these research initiatives and encouraging partnerships with international firms. As development activities progress, they're expanding the range of applications for plasma products while enhancing their availability throughout the healthcare system, ultimately strengthening confidence in plasma-based therapies.

Saudi Arabia Plasma Fractionation Market Trends:

● Government Support and Healthcare Infrastructure Investment

The Saudi government is actively strengthening healthcare infrastructure through substantial investments aimed at enhancing the country's medical capabilities. Government initiatives are specifically targeting the expansion of blood collection facilities, improvement of storage capabilities, and development of advanced fractionation technologies. These efforts include funding for research institutions working on plasma-derived therapies and support for establishing partnerships with international pharmaceutical companies. In March 2023, the Ministry of Health organized a Plasma Fractionation and Hemovigilance Workshop in Riyadh in cooperation with the Arab Authority for Blood Transfusion and Blood Banks Friends Charity. The event brought together national and international experts to share best practices on plasma collection and fractionation, supporting further developments and key decision-making in the Kingdom. This kind of government-led collaboration demonstrates the commitment to building self-sufficiency in plasma products while maintaining the highest quality standards.

● Adoption of Advanced Fractionation Technologies

Saudi Arabia's plasma fractionation sector is witnessing the integration of cutting-edge separation technologies that significantly improve product quality and yield. Modern chromatographic techniques are becoming more prevalent, enabling better purification of plasma components and the development of new therapeutic products with enhanced safety profiles. These advanced methods allow for more precise isolation of proteins like immunoglobulins, albumin, and clotting factors while minimizing the risk of contamination. Healthcare facilities and pharmaceutical companies operating in the Kingdom are investing in state-of-the-art equipment that can process plasma more efficiently, meeting international quality standards. The adoption of these technologies is also supporting the production of specialized plasma derivatives that address specific medical needs, particularly for rare blood disorders and immune deficiencies. This technological advancement is helping position Saudi Arabia as a regional hub for high-quality plasma product manufacturing.

● Focus on Self-Sufficiency and Domestic Production

There's a growing emphasis on developing domestic plasma collection and fractionation capabilities to reduce reliance on imported products and ensure stable supply chains. The Kingdom is working toward establishing comprehensive plasma programs that encompass everything from donor recruitment to final product distribution. Healthcare authorities are collaborating with international companies like Kedrion, which has presented workshops on contract manufacturing and self-sufficiency programs in Saudi Arabia. These partnerships aim to transfer knowledge and technology while building local capacity for plasma processing. The focus extends beyond just manufacturing to include establishing proper quality control systems, training local personnel, and implementing international best practices in plasma safety. This strategic approach is designed to secure long-term access to essential plasma-derived medications while also creating economic opportunities within the country's biotechnology and pharmaceutical sectors.

Recent News and Developments in Saudi Arabia Plasma Fractionation Market

March 2024: Takeda Pharmaceutical Company commissioned a new plasma fractionation plant in Osaka, Japan, significantly increasing its global production capacity to meet growing worldwide demand for plasma-derived therapies. This expansion strengthens the company's ability to serve markets including Saudi Arabia and the broader Middle East region, where demand for immunoglobulins and coagulation factors continues to rise.

● June 2024: Biotest, a global plasma protein products supplier under Grifols, received FDA approval for marketing Yimmugo, a treatment for primary humoral immunodeficiency in patients aged two years and older. The approval of this new therapy provides additional treatment options for patients with immune deficiencies who depend on plasma-derived medicines, expanding the portfolio of available immunoglobulin products in global markets.

● July 2024: Grifols announced plans to open a new manufacturing facility in Barcelona, Spain, with the goal of doubling its current European production capacity. The new facility is expected to become operational in 2030 and will significantly expand the company's manufacturing output in the region, supporting growing global demand including markets in the Middle East where Grifols maintains a strong presence.

● August 2024: Nanoform Finland partnered with Takeda Pharmaceutical Company to develop pre-clinical plasma-derived therapies aimed at treating rare diseases. The collaboration focuses on improving drug formulations and therapeutic performance, with particular emphasis on developing better treatment options for conditions like hemophilia and primary immunodeficiencies that require specialized plasma-derived medications.

● September 2024: GEFD, a joint venture between Grifols and Egypt's National Service Project Organization, launched a national initiative to achieve self-sufficiency in plasma-derived medicines across the region. The project includes establishing a plasma laboratory, storage facility, 20 donation centers, and an advanced manufacturing plant, demonstrating the growing regional focus on developing local plasma fractionation capabilities similar to Saudi Arabia's objectives.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.